Meridian Bioscience Named Top Dividend Stock With Insider Buying and 4.52% Yield (VIVO)

In this series, we look through the most recent Dividend Channel ''DividendRank'' report, and then we cherry pick only those companies that have experienced insider buying within the past six months. The officers and directors of a company tend to have a unique insider's view of the business, and presumably the only reason an insider would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both. So when stocks turn up that see insider buying, and are also top ranked, investors are wise to take notice. One such company is Meridian Bioscience Inc. (VIVO), which saw buying by Director Dwight E. Ellingwood.

START SLIDESHOW:
The Top DividendRank'ed Stocks With Insider Buying »

Back on January 23, Ellingwood invested $35,125.99 into 1,980 shares of VIVO, for a cost per share of $17.74. In trading on Friday, bargain hunters could buy shares of Meridian Bioscience Inc. ( VIVO) and achieve a cost basis 0.8% cheaper than Ellingwood, with shares changing hands as low as $17.59 per share. It should be noted that Ellingwood has collected $0.40/share in dividends since the time of their purchase, so they are currently up 1.4% on their purchase from a total return basis. Meridian Bioscience Inc. shares are currently trading -0.11% on the day. The chart below shows the one year performance of VIVO shares, versus its 200 day moving average:

Meridian Bioscience Inc. Chart

Looking at the chart above, VIVO's low point in its 52 week range is $15.56 per share, with $21.33 as the 52 week high point — that compares with a last trade of $17.70. By comparison, below is a table showing the prices at which insider buying was recorded over the last six months:

Purchased Insider Title Shares Price/Share Value
11/11/2014 David Phillips Director 10,000 $16.89 $168,924.00
11/21/2014 Dwight E. Ellingwood Director 1,000 $16.08 $16,082.90
01/23/2015 Dwight E. Ellingwood Director 1,980 $17.74 $35,125.99

The DividendRank report noted that among the coverage universe, VIVO shares displayed both attractive valuation metrics and strong profitability metrics. The report also cited the strong quarterly dividend history at Meridian Bioscience Inc., and favorable long-term multi-year growth rates in key fundamental data points.

The report stated, '' Dividend investors approaching investing from a value standpoint are generally most interested in researching the strongest most profitable companies, that also happen to be trading at an attractive valuation. That's what we aim to find using our proprietary DividendRank formula, which ranks the coverage universe based upon our various criteria for both profitability and valuation, to generate a list of the top most 'interesting' stocks, meant for investors as a source of ideas that merit further research.''

The annualized dividend paid by Meridian Bioscience Inc. is $0.80/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 04/30/2015. Below is a long-term dividend history chart for VIVO, which the report stressed as being of key importance. Indeed, studying a company's past dividend history can be of good help in judging whether the most recent dividend is likely to continue.

VIVO+Dividend+History+Chart

More from Stocks

Abercrombie & Fitch CEO: We Aren't the Same Abercrombie You Once Knew

Abercrombie & Fitch CEO: We Aren't the Same Abercrombie You Once Knew

Amazon Wants to Use Your Car as a Mobile Warehouse - Here's What That Could Mean

Amazon Wants to Use Your Car as a Mobile Warehouse - Here's What That Could Mean

Chipotle's New CEO Has Set its Path for Redemption

Chipotle's New CEO Has Set its Path for Redemption

TheStreet Is About to Hold the BEST Institutional Investor Conference of 2018

TheStreet Is About to Hold the BEST Institutional Investor Conference of 2018

Twitter's Turnaround Continues but Investors Don't Seem Entirely Convinced

Twitter's Turnaround Continues but Investors Don't Seem Entirely Convinced